TrialBlood2019
Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.
Philip A Thompson et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
41 papers cite it
this papertrialcites it